Eli Lilly and Company discovers ... severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis ...

US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct ... along with diagnostics and treatments for COVID-19, flu, respiratory syncytial virus, and migraine.

Moderna norovirus vaccine trial on hold by US FDA over neurological side effect Eli Lilly investors and analysts ... citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing ...

UnitedHealth Group CEO says complex US healthcare system needs to change Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall ...

Your local pharmacy might be the next front in Donald Trump’s trade war. The president has in recent weeks promised to impose tariffs on all foreign-made medications, a move intended to encourage drug ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...